SOHM, Inc. Subsidiary Daiichi Sankyo Group Files Its Acute Myeloid Leukemia (AML) Treatment Quizartinib in the US; the FDA Awarded Breakthrough Status for The Drug
Aug. 09, 2018
Chino Hills, CA, Aug. 09, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN), a globally-known generic pharmaceutical manufacturer, announced that its subsidiary Daiichi Sankyo Group filed its acute myeloid leukemia (AML) treatment Quizartinib in the US; the FDA awarded breakthrough status for the drug.
Results from the pivotal QuANTUM-R study were presented at the European Heart Association (EHA) meeting in June, and showed patients treated with the FLT3 inhibitor reached a median overall survival of 6.2 months, compared to 4.7 months for patients treated with salvage chemotherapy. After a year, survival was 26% with Daiichi Sankyo’s drug and 20% in the placebo group. The data suggest that Quizartinib could have an advantage over the only other approved treatment in the same class, Novartis’ Rydapt (midostaurin), which was approved in Europe last year, and puts the Japanese company on course to get a return on its $410m acquisition of the drug’s originator Ambit Biosciences in 2014.
SOHM, Inc. continues to work and expand. The Company is focused on sales and bringing value to its loyal stakeholders. The company’s legal team is continuing to work with the OTC Markets to fulfill all necessary documentation to remove our Stop sign and become fully current.
About SOHM, Inc.SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a global presence and marketing plan that assure continuous growth. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing in India as well as strategic alliance with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and was introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.To know more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact: SOHM, Inc. 714-522-6700